

1102865-0034

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Gevas et al.	:		RECEIVED
Serial No.:	09/700,402	<i>)</i> :	Examiner: To be assigned	JUL 0 5 2001
Filed:	November 14, 2000) :	Group Art Unit: To be assigned	TECH CENTER 1600/2900

Title:

COMBINATION THERAPY FOR THE TREATMENT OF TUMORS

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents Washington, D. C. 20231.

Thelma A. Chen Cleland 40,948

Name Reg. No.

Helma A. Chen Cleland 6/20/01

Signature Date

INFORMATION DISCLOSURE STATEMENT

BOX PCT Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the provisions of MPEP §609 and 37 CFR §1.97 and 1.98, enclosed for consideration by the Examiner are copies of the references listed on the attached Form PTO-1449.

This paper is submitted prior to the mailing of the first Office Action on the merits in the above-identified application. Therefore, no fee is due. However, the Commissioner is hereby authorized to charge any required fee with this paper to Deposit Account No. 23-1703.

Applicants respectfully request favorable consideration and entry hereof.

Dated: June 20, 2001

Respectfully submitted,

Thelma A. Chen Cleland

Thelma a. Chen Cleland

Reg. No. 40,948 (212) 819-8515

Applicants' Agent Customer No. 007470 (212) 819-8200

Enclosures



TECH CENTER 1600/2900 $_{\rm age~1~of~2}$

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Atty. Docket No.	Serial No.
(REV. 2-82)	PATENT AND TRADEMARK OFFICE	1102865-0034	09/700,402
INFORMA	ATION DISCLOSURE STATEMENT	Applicant: Gevas et al.	
	BY APPLICANT		
		Filing Date:	Group:
		11/14/2000	TBA

UNITED STATES PATENT DOCUMENTS

*Examiner Initial	Document No.						Date	Name	Class	Sub-Class	Filing Date, if Appropriate

FOREIGN PATENT DOCUMENTS

*Examiner Initial	Document No.	Date Country		Class	Sub-Class	Translation Yes No	

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

Dickinson, C.J. "Relationship of gastrin processing to colon cancer". Gastroenterology, 109: 1384-1388, 1995.
Rehfeld et al. "Three components of gastrin in human serum". Biochim. Biophys. Acta., 285: 364-372, 1972.
Moertel, G.G. "Chemotherapy CRC'. NEJM 1994; 330:1136-1142.
Mahood, et al. "Inhibition of fluorouracil stomatitis by oral cryotherapy". J Clin Oncol 1991; 9: 449-452.
Pietnelli, et al. "The modulation of Fluorouracil with leucovorin in metastatic CRC: a prospective randomized phase III trial". J Clin Oncol 1989; 7: 1419-1426.

Examiner:

Date Considered:

*Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.





TECH CENTER 1600/2900 Page 2 of 2

									,	0=141=11100	ישונים	JUU Fage	2 01 2		
FORM PTO-1449 U.S. DEPARTM (REV. 2-82) PATENT AND									1 -	Atty. Docket No. 1102865-0034			Serial No.		
	INFO	RMA'				LOS	Applicant:	Applicant:							
							Filing Date	Filing Date:			Group:				
					U	NIT	ED STATE	S PATENT DOCU	MENTS						
*Examiner Initial	Document No.						Date	Name	Class	Sub-Cla	SS	-	ling Date, if opropriate		
															
				_		F	OREIGN PA	ATENT DOCUME	NTS		_				
*Examiner Initial				Document No.			Date Country		Class	Sub-Cla	ass Translation Yes No				
							1								
		OTH	łER I))	CUM	1EN	TS (includin	g Author, Title, Da	te, Pertinent Pa	ges, Etc.)					
		Bock, et al. "Benzodiazepine, gastrin and brain cholecystokinin receptor ligands: L-365,260. J. Med. Chem., 32: 13-17, 1989.										Med.			
		_					-	lass of selective cho Natl. Acad. Sci., 87	•		anta	agonists h	aving		
		Watson, et al. "Gastrimmune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer". Cancer Res. 1996; 56: 880-885.										trin-17			
								ation against gastri Gastroenterol 199		terminal deriv	ved i	immunoge	en inhibits		
							on of trypsin 1983; 32: 62	of 2 sublines of rat 3-627.	cancer cells for	ming progress	sive	or regress	sive		
			_									_	_		

Examiner:

Date Considered:

*Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.